Thank you ICEMAN, I'm only down 50% now, hopefully next week we will be back to $40.
M
-- Five-fold increase in net sales of TAVNEOS® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 --
-- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison):
- 195% TAVNEOS new Patient Start Forms
- 275% Unique Prescribers
- 308% Patients on Drug --
-- Global expansion continues with approvals in European Union (EU) and Canada; $45 million milestone received from TAVNEOS EU approval --
-- Positive Phase I data on pharmacokinetics (PK) and pharmacodynamics (PD) including evidence of immune activation for once daily, orally administered PD-L1 inhibitor, CCX559 --
-- Well capitalized with approximately $371.8 million in cash and investments as of March 31, 2022 --
C
Raymond James was right, Revenue beat estimates, their price target is $106. They believe CCXI has a blockbuster drug, with no competition is sight.
H
From $40 to this in 30 days!
N
I didn't sold this scam at 40 now I am all in loss all those paid dogs are gone who were saying bullish..........CEO all Member didn't have any answer for that down how can a share drop 25$ for no reason
P
Well, there's some who liked the earnings call, at least. IBKR says nearly 12k volume with pre-market having been open for 30 minutes so far, and it's keeping the green it gained AH.
P
2 Things:
1 - "Aug 19 $20 Calls Sweep (47) Near The Ask: 996 @ $2.5 vs 835 OI; Ref=$16.69" (Via BZ)
2 - "JPMorgan maintained coverage with Neutral and target of $34" (Via StreetInsider)
So this is definitely going back up in the medium/long term.
B
Very, very unfortunate that I didn’t Sell all of my shares in the $30s’. I guess my last 25 shares will go sub $15 soon, unreal. A Performance (Year To Date) of 🔻-51.44%. ICEMAN Cometh & Tooketh. Rare Disease John was right too, my bad.
s
The closing price today is now below the closing price 6 months ago the day before the FDA acceptance was announced.
A
Blockbuster drug doesn’t interfere with your immune system.. awesome findings.
B
Just got a notice that the earnings report will come out after hours today. Anyone have any thoughts if this will tank even lower or if it will jump up? Thanks.
S
Well, we must all admit, the ICEMAN had warned us and is the only one left standing tall here. Congratulations ICEMAN on your perfect call!
A
80$ company
A
sales will grow exponentially
B
Where has my $19+ intraday price action gone?
r
I need this back up to at least 30 cmon
A
nice results. almost 6m $ rev in the US. starting well.
C
Strong launch of a Blockbuster drug. Raymond James believe they will beat estimates on the 5th.
P
A message to investors...if we believe that employees make the company...then we best be careful as if you read "glassdoor" about CCXI you get the feeling that management is not so cool. Execution of a Vision is best served by a CEO with a vision.
-- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison):
- 195% TAVNEOS new Patient Start Forms
- 275% Unique Prescribers
- 308% Patients on Drug --
-- Global expansion continues with approvals in European Union (EU) and Canada; $45 million milestone received from TAVNEOS EU approval --
-- Positive Phase I data on pharmacokinetics (PK) and pharmacodynamics (PD) including evidence of immune activation for once daily, orally administered PD-L1 inhibitor, CCX559 --
-- Well capitalized with approximately $371.8 million in cash and investments as of March 31, 2022 --
1 - "Aug 19 $20 Calls Sweep (47) Near The Ask: 996 @ $2.5 vs 835 OI; Ref=$16.69" (Via BZ)
2 - "JPMorgan maintained coverage with Neutral and target of $34" (Via StreetInsider)
So this is definitely going back up in the medium/long term.
Thanks.